Dose Reduction of Postoperative Radiation for Soft Tissue Sarcoma of the Arms and Legs

  • STATUS
    Recruiting
  • participants needed
    60
  • sponsor
    Memorial Sloan Kettering Cancer Center
Updated on 19 February 2024
serum pregnancy test
sarcoma
primary tumor
soft tissue sarcoma
sarcoma of the extremity

Summary

The investigators are doing this study to find out whether lowering the dose of postoperative radiation therapy and targeting a smaller area of tissue for treatment is as effective as the standard dose and volume of radiation therapy to control soft tissue sarcoma after surgery. They also want to find out whether the study approach causes fewer and less severe long-term side effects than the standard approach.

Details
Condition Connective and Soft Tissue Neoplasm, Solid Tumors, Sarcoma, Sarcoma, Solid Tumors
Age 18-100 years
Treatment Intensity-modulated radiation therapy (IMRT)
Clinical Study IdentifierNCT04288375
SponsorMemorial Sloan Kettering Cancer Center
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients must be diagnosed with a primary soft tissue sarcoma of the extremity, confirmed by MSKCC pathologic review
Age at the time of enrollment of 18 years
Patients must have undergone margin-negative oncologic resection of their primary tumor, as confirmed by MSKCC pathologic review
Patients must be able to start radiation within 3 months from time of surgery
Female patients of childbearing potential must have a negative serum pregnancy test within 14 days of radiation start (or if urine test, within 24 hours of radiation start)
Sexually active patients of childbearing potential must agree to use effective contraception
The use of chemotherapy will not be dictated by this trial. Patients are allowed to receive chemotherapy at the discretion of the disease management team (as is standard practice to make individualized decisions for each patient regarding the use of chemotherapy)

Exclusion Criteria

Patients with positive margins after surgical resection as indicated by MSKCC pathologic review
Patients with diagnosis of superficial myxofibrosarcoma with indistinct/infiltrative borders on preoperative MRI16 (see Appendix Figure 1 for reference figure) or <70% myxoid component given the distinct failure pattern in these patients14
Patients with multifocal disease in the extremity
Patients who have received prior radiotherapy at or adjacent to the primary tumor bed
Patients with a differentinvasive cancer requiring active treatment at the time of enrollment
Patients with any concurrent medical or psychiatric condition or disease which, in the investigator's judgment, would make them inappropriate candidates for entry into this study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.